GSK2118436: Phase III started

GlaxoSmithKline began the open-label, international Phase III BRF113683 trial to compare twice-daily 150 mg GSK2118436 vs. 1,000 mg/m 2 IV dacarbazine every 3 weeks in 200 treatment-naïve patients wit...